Membranous Glomerulonephritis Workup
- Author: Abeera Mansur, MD; Chief Editor: Vecihi Batuman, MD, FACP, FASN more...
See the list below:
- Urine microscopy: Urine sediment is typically nephrotic, with oval fat bodies and fatty casts; however, in mild cases, the urinalysis may reveal proteinuria without formed elements in the sediment.
- Serum creatinine
- Blood urea nitrogen
- Serum albumin
- Proteinuria (quantitative) with a 24-hour urine collection: A ratio of spot urine protein to creatinine is easier to obtain, and the findings may be sufficient for screening purposes.
- Creatinine clearance
- Antinuclear antibodies
- Anti–double-strand DNA, if results from antinuclear antibody testing are positive
- Hepatitis B serology (if positive, DNA quantitation)
- Hepatitis C (if positive, RNA quantitation)
- Syphilis serology
- Complement levels
- Cryoglobulin, particularly if hepatitis C and/or low levels of complement are found
- Lipid profile
- Urinary C5b-9
- Urinary beta-2 microglobulin (worse prognosis with an increased level)
- Malignancy workup: An exhaustive workup for malignancy is not recommended because most cases of membranous nephropathy are not associated with cancer. However, because some increase in the rate of occult malignancy is recognized in patients with newly diagnosed membranous nephropathy, (1) ensure that age-appropriate health screening (eg, mammography, sigmoidoscopy) has been performed, and (2) investigate any clues from the initial patient history and physical examination.
See the list below:
See the list below:
- Renal biopsy: Definitive diagnosis is made based on findings from a renal biopsy.
Pathologic features can be observed using light microscopy, immunofluorescence microscopy, and electron microscopy.
- Light microscopy: The mesangium is normal, with no hypercellularity. All glomeruli are involved. The capillary walls are thickened with patent capillary lumina. Subepithelial deposits are seen; with trichrome stain, they are shown to have spikes.
- Immunofluorescence microscopy: Use strong granular capillary wall staining for immunoglobulin G (IgG), with C3 and both kappa and lambda light chains.
- Electron microscopy
- A considerable diversity of prognosis is seen with idiopathic membranous nephropathy. In a study of 105 patients with idiopathic membranous nephropathy, 2 different groups were identified on the electron microscopic findings. In the homogeneous type, only 1 patient developed end-stage renal failure, and earlier remission occurred in this group. With regard to secondary outcome, increased age, focal segmental glomerular sclerosis, arteriolosclerosis, and heterogeneous type of electron microscopic findings were independent risk factors.
- Stage 1: Features appear normal using light microscopy, but, with electron microscopy, a few electron-dense deposits are seen along the capillary walls.
- Stage 2: Numerous and larger deposits with spikes are seen.
- Stage 3: New extracellular material surrounds the deposits.
- Stage 4: Initial electron-dense deposits become electron-lucent, and capillary walls become thickened.
Ronco P, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens. 2006 May. 15(3):258-63. [Medline].
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009 Jul 2. 361(1):11-21. [Medline]. [Full Text].
Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011 Jun 2. 364(22):2101-10. [Medline].
Chen A, Frank R, Vento S, et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol. 2007 Aug 6. 8:11. [Medline].
El Kossi M, Harmer A, Goodwin J, et al. De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant. 2008 Jan-Feb. 22(1):124-7. [Medline].
Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012 Jan. 7(1):43-51. [Medline]. [Full Text].
Polenakovic M, Grcevska L, Dzikova S. 20 years after methylprednisolone/chlorambucil treatment in idiopathic membranous nephropathy stage II-III with nephrotic syndrome. Prilozi. 2006 Dec. 27(2):5-12. [Medline].
[Guideline] Kidney Disease Improving Global Outcomes. KDIGO Clinical Practice Guidelines for Glomerulonephritis. Available at http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf. Accessed: January 6, 2014.
Branten AJ, du Buf-Vereijken PW, Vervloet M, et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis. 2007 Aug. 50(2):248-56. [Medline].
Ruggenenti P, Cravedi P, Remuzzi G. Latest treatment strategies for membranous nephropathy. Expert Opin Pharmacother. 2007 Dec. 8(18):3159-71. [Medline].
Cravedi P, Ruggenenti P, Sghirlanzoni MC, et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007 Sep. 2(5):932-7. [Medline].
Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008 Jan. 73(1):117-25. [Medline].
Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol. 2013 Mar. 9(3):154-69. [Medline].
Hogan J, Mohan P, Appel GB. Diagnostic Tests and Treatment Options in Glomerular Disease: 2014 Update. Am J Kidney Dis. 2013 Nov 14. [Medline].
Chuang TW, Hung CH, Huang SC, et al. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc. 2007 Oct. 106(10):869-73. [Medline].
Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006 May. 69(9):1641-8. [Medline].
Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis. 1987 Sep. 10(3):157-71. [Medline].
Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002 Mar. 61(3):1098-114. [Medline].
Coupes B, Brenchley PE, Short CD, et al. Clinical aspects of C3dg and C5b-9 in human membranous nephropathy. Nephrol Dial Transplant. 1992. 7 Suppl 1:32-4. [Medline].
Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol. 2005 May. 16(5):1214-22. [Medline].
Haas M, Meehan SM, Karrison TG, et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997 Nov. 30(5):621-31. [Medline].
Hogan SL, Muller KE, Jennette JC, et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis. 1995 Jun. 25(6):862-75. [Medline].
Honkanen E, Tornroth T, Gronhagen-Riska C. Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transplant. 1992. 7 Suppl 1:35-41. [Medline].
Hunt LP. Statistical aspects of survival in membranous nephropathy. Nephrol Dial Transplant. 1992. 7 Suppl 1:53-9. [Medline].
Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005 Jul. 68(1):302-10. [Medline].
Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int. 1995 Jan. 47(1):225-30. [Medline].
Muirhead N. Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int Suppl. 1999 Jun. 70:S47-55. [Medline].
Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol. 2005 May. 16(5):1195-204. [Medline].
Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995 Nov. 48(5):1600-4. [Medline].
Reichert LJ, Koene RA, Wetzels JF. Prognostic factors in idiopathic membranous nephropathy. Am J Kidney Dis. 1998 Jan. 31(1):1-11. [Medline].
Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol. 1995 Dec. 6(6):1666-9. [Medline].
Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003 Jul. 14(7):1851-7. [Medline].
Schieppati A, Perna A, Zamora J, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2004 Oct 18. CD004293. [Medline].
Yokoyama H, Yoshimoto K, Wada T. [Membranous nephropathy]. Nippon Rinsho. 2004 Oct. 62(10):1856-60. [Medline].